AZUR-4, a phase 2, open label, randomized study of neoadjuvant dostarlimab plus capecitabine plus oxaliplatin (CAPEOX) versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer.

Authors: Gertjan Rasschaert, Allyson Peddle, Sabine Tejpar, Nick West, Jenny Ross, Julie C. Switzky, Ken Edwards, Gabor Kari, Suzanne Griffin, Chiuwa Emily Luk, Daniel N. Cohen, Emily Hammatt, Edmund Moon

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps3649

Source: Full article

---

Abstract

TPS3649